CVS Stock Recent News
CVS LATEST HEADLINES
Three Fortune 500 Industry Leaders—Energy Transfer, Verizon, and World Kinect—currently meet the 'dogcatcher' ideal of fair price and safer dividends. Analyst targets project 21% to 50% net gains for the top ten F500IL dividend dogs by June 2026, with average gains of 28.8%. Most top-yielding F500IL stocks remain overpriced, but a 60% market correction or dividend increases could make all ten fairly priced for income investors. Twelve F500IL stocks have negative free cash flow margins, making them unsafe for dividends; focus on the three 'safer' fair-priced options for now.
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS gains steam as rising margins, strong Medicare results, and cost cuts set it apart from UNH.
CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.
CVS surges 53.7% YTD as regulatory relief, strong execution and Medicare Advantage momentum fuel investor confidence.
The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.
CVS, BTSG and WGS are three medical services stocks tapping into AI and tech-driven care to boost diagnostics, cut costs and drive growth in 2025.
As geopolitical risks jolt markets, STNE, CNC, CVS and PFE shine with low cash flow valuations and solid earnings outlooks.
Here are four discounted PEG stocks that qualify our screening criteria and could be good picks. These are FLEX, CVS, URBN and EXEL.
CVS posts its first favorable MBR in quarters, but elevated cost trends test its ability to sustain the gains.